Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to email@example.com so that we can defer those challenges. Your health and safety are paramount to us.
Posted 10 February 2015 | By Michael Mezher
The European Medicines Agency (EMA) is looking to increase transparency between its committees and pharmaceutical companies under a new guideline that went into effect in February 2015.
The guideline, EMA/636600/2014, details procedures regarding clarification meetings in response to questions raised by the agency during the review of a product using the centralized procedure.
EMA believes increasing transparency between the agency and applicants regarding objections, which can range from questions about pharmacodynamics to issues raised with a company’s risk management plan, can improve the quality of companies’ responses and reduce review times for new drugs.
The guideline covers the objectives, procedures and content of meetings between a company and relevant EMA committees to discuss the company’s response strategy to Day 120 List of Questions (LoQ) or Day 180 List of Outstanding Issues (LoOI).
In EMA’s centralized procedure an LoQ is adopted by the Committee for Medicinal Products for Human Use (CHMP) at day 120 of the procedure, detailing the committee’s questions about an application, an applicant is then able to submit a response to those questions. EMA then has until the day 180 of the procedure to review the company’s response. If further objections are raised, an LoOI is sent to an applicant at day 180.
According to the guideline, the response strategy meetings will be chaired by the CHMP rapporteur. Co-rapporteurs may include members of other relevant committees, such as EMA's Pharmacovigilance Risk Assessment Committee (PRAC) or Committee for Advanced Therapies (CAT). Also present will be an EMA Product Lead (EPL), whose role is to oversee a product throughout its lifecycle and “provide regulatory science input … [to] the EMA’s scientific committees."
Companies are told to submit documents detailing their response strategy, including an explanation of any points they want clarified, to the rapporteurs at least one week in advance of the meeting date.
Applicants must take minutes of the meeting, to be sent within one week to the rapporteurs and EPL for comment. The EMA then has two weeks to return a final version to the applicant. The final minutes are required to be attached to the cover letter of the company’s formal response to the agency.
EMA makes clear in the guideline that “these meetings are not intended to provide a pre-assessment of the Applicant’s intended responses.” Additionally, the position(s) presented by the (co-)rapporteurs will not “preempt the outcome of the assessment,” and is not binding to the committees involved.
Tags: List of Questions, List of Outstanding Issues, LoQ, LoOI, CHMP, EMA Product Lead